Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
InfiltrateID utilizes a single-sample gene set enrichment analysis (ssGSEA) approach to compute transcriptome-based enrichment scores for eight distinct immune cell types (Table 1) from a single tumor sample, quantifying the abundance of those populations within the TME of that sample. Personalis has developed in-house proprietary cell type-specific signatures for eight distinct immune cell types using our augmented gene expression data, derived from purified immune cell populations. Each signature consists of genes curated based on a strict selection criterion, requiring consistent expression and low expression variability in each of the eight immune cell types.
